nivolumab biosimilar (JPB-898) / Sandoz - LARVOL DELTA

NivoReach: Integrated study to demonstrate similarity of JPB898 to reference nivolumab in combination with ipilimumab in patients with advanced melanoma. (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT06587451 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Combination therapy • Metastases • Melanoma • Oncology • Solid Tumor

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® (clinicaltrials.gov) - P3 | N=720 | Recruiting | Sponsor: Sandoz | Not yet recruiting ➔ Recruiting

Enrollment open • Melanoma • Oncology • Solid Tumor